CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Inhalable Insulin
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Oral Insulin
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Insulin Patches
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 CGM Systems
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Artificial Pancreas
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
CHAPTER 5: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC
5.1 Overview
5.1.1 Market size and forecast
5.2 Adult Population (>14years)
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Child Population (14years)
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Type 1 Diabetes
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Type 2 Diabetes
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER
7.1 Overview
7.1.1 Market size and forecast
7.2 Diagnostic/Clinics
7.2.1 Key market trends, growth factors and opportunities
7.2.2 Market size and forecast, by region
7.2.3 Market analysis by country
7.3 ICUs
7.3.1 Key market trends, growth factors and opportunities
7.3.2 Market size and forecast, by region
7.3.3 Market analysis by country
7.4 Home Healthcare
7.4.1 Key market trends, growth factors and opportunities
7.4.2 Market size and forecast, by region
7.4.3 Market analysis by country
CHAPTER 8: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY REGION
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key trends and opportunities
8.2.2 North America Market size and forecast, by Product
8.2.3 North America Market size and forecast, by Demographic
8.2.4 North America Market size and forecast, by Indication
8.2.5 North America Market size and forecast, by End User
8.2.6 North America Market size and forecast, by country
8.2.6.1 U.S.
8.2.6.1.1 Market size and forecast, by Product
8.2.6.1.2 Market size and forecast, by Demographic
8.2.6.1.3 Market size and forecast, by Indication
8.2.6.1.4 Market size and forecast, by End User
8.2.6.2 Canada
8.2.6.2.1 Market size and forecast, by Product
8.2.6.2.2 Market size and forecast, by Demographic
8.2.6.2.3 Market size and forecast, by Indication
8.2.6.2.4 Market size and forecast, by End User
8.2.6.3 Mexico
8.2.6.3.1 Market size and forecast, by Product
8.2.6.3.2 Market size and forecast, by Demographic
8.2.6.3.3 Market size and forecast, by Indication
8.2.6.3.4 Market size and forecast, by End User
8.3 Europe
8.3.1 Key trends and opportunities
8.3.2 Europe Market size and forecast, by Product
8.3.3 Europe Market size and forecast, by Demographic
8.3.4 Europe Market size and forecast, by Indication
8.3.5 Europe Market size and forecast, by End User
8.3.6 Europe Market size and forecast, by country
8.3.6.1 Germany
8.3.6.1.1 Market size and forecast, by Product
8.3.6.1.2 Market size and forecast, by Demographic
8.3.6.1.3 Market size and forecast, by Indication
8.3.6.1.4 Market size and forecast, by End User
8.3.6.2 France
8.3.6.2.1 Market size and forecast, by Product
8.3.6.2.2 Market size and forecast, by Demographic
8.3.6.2.3 Market size and forecast, by Indication
8.3.6.2.4 Market size and forecast, by End User
8.3.6.3 U.K.
8.3.6.3.1 Market size and forecast, by Product
8.3.6.3.2 Market size and forecast, by Demographic
8.3.6.3.3 Market size and forecast, by Indication
8.3.6.3.4 Market size and forecast, by End User
8.3.6.4 Italy
8.3.6.4.1 Market size and forecast, by Product
8.3.6.4.2 Market size and forecast, by Demographic
8.3.6.4.3 Market size and forecast, by Indication
8.3.6.4.4 Market size and forecast, by End User
8.3.6.5 Spain
8.3.6.5.1 Market size and forecast, by Product
8.3.6.5.2 Market size and forecast, by Demographic
8.3.6.5.3 Market size and forecast, by Indication
8.3.6.5.4 Market size and forecast, by End User
8.3.6.6 Rest of Europe
8.3.6.6.1 Market size and forecast, by Product
8.3.6.6.2 Market size and forecast, by Demographic
8.3.6.6.3 Market size and forecast, by Indication
8.3.6.6.4 Market size and forecast, by End User
8.4 Asia-Pacific
8.4.1 Key trends and opportunities
8.4.2 Asia-Pacific Market size and forecast, by Product
8.4.3 Asia-Pacific Market size and forecast, by Demographic
8.4.4 Asia-Pacific Market size and forecast, by Indication
8.4.5 Asia-Pacific Market size and forecast, by End User
8.4.6 Asia-Pacific Market size and forecast, by country
8.4.6.1 China
8.4.6.1.1 Market size and forecast, by Product
8.4.6.1.2 Market size and forecast, by Demographic
8.4.6.1.3 Market size and forecast, by Indication
8.4.6.1.4 Market size and forecast, by End User
8.4.6.2 Japan
8.4.6.2.1 Market size and forecast, by Product
8.4.6.2.2 Market size and forecast, by Demographic
8.4.6.2.3 Market size and forecast, by Indication
8.4.6.2.4 Market size and forecast, by End User
8.4.6.3 India
8.4.6.3.1 Market size and forecast, by Product
8.4.6.3.2 Market size and forecast, by Demographic
8.4.6.3.3 Market size and forecast, by Indication
8.4.6.3.4 Market size and forecast, by End User
8.4.6.4 Australia
8.4.6.4.1 Market size and forecast, by Product
8.4.6.4.2 Market size and forecast, by Demographic
8.4.6.4.3 Market size and forecast, by Indication
8.4.6.4.4 Market size and forecast, by End User
8.4.6.5 South Korea
8.4.6.5.1 Market size and forecast, by Product
8.4.6.5.2 Market size and forecast, by Demographic
8.4.6.5.3 Market size and forecast, by Indication
8.4.6.5.4 Market size and forecast, by End User
8.4.6.6 Rest of Asia-Pacific
8.4.6.6.1 Market size and forecast, by Product
8.4.6.6.2 Market size and forecast, by Demographic
8.4.6.6.3 Market size and forecast, by Indication
8.4.6.6.4 Market size and forecast, by End User
8.5 LAMEA
8.5.1 Key trends and opportunities
8.5.2 LAMEA Market size and forecast, by Product
8.5.3 LAMEA Market size and forecast, by Demographic
8.5.4 LAMEA Market size and forecast, by Indication
8.5.5 LAMEA Market size and forecast, by End User
8.5.6 LAMEA Market size and forecast, by country
8.5.6.1 Brazil
8.5.6.1.1 Market size and forecast, by Product
8.5.6.1.2 Market size and forecast, by Demographic
8.5.6.1.3 Market size and forecast, by Indication
8.5.6.1.4 Market size and forecast, by End User
8.5.6.2 Saudi Arabia
8.5.6.2.1 Market size and forecast, by Product
8.5.6.2.2 Market size and forecast, by Demographic
8.5.6.2.3 Market size and forecast, by Indication
8.5.6.2.4 Market size and forecast, by End User
8.5.6.3 South Africa
8.5.6.3.1 Market size and forecast, by Product
8.5.6.3.2 Market size and forecast, by Demographic
8.5.6.3.3 Market size and forecast, by Indication
8.5.6.3.4 Market size and forecast, by End User
8.5.6.4 Rest of LAMEA
8.5.6.4.1 Market size and forecast, by Product
8.5.6.4.2 Market size and forecast, by Demographic
8.5.6.4.3 Market size and forecast, by Indication
8.5.6.4.4 Market size and forecast, by End User
CHAPTER 9: COMPANY LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Key developments
CHAPTER 10: COMPANY PROFILES
10.1 Abbott laboratories
10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Operating business segments
10.1.4 Product portfolio
10.1.5 Business performance
10.1.6 Key strategic moves and developments
10.2 Dexcom, Inc
10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Operating business segments
10.2.4 Product portfolio
10.2.5 Business performance
10.2.6 Key strategic moves and developments
10.3 Eli Lilly and Company
10.3.1 Company overview
10.3.2 Company snapshot
10.3.3 Operating business segments
10.3.4 Product portfolio
10.3.5 Business performance
10.3.6 Key strategic moves and developments
10.4 Glysens Incorporated
10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Operating business segments
10.4.4 Product portfolio
10.4.5 Business performance
10.4.6 Key strategic moves and developments
10.5 Johnson & Johnson
10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Operating business segments
10.5.4 Product portfolio
10.5.5 Business performance
10.5.6 Key strategic moves and developments
10.6 MannKind Corporation
10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Operating business segments
10.6.4 Product portfolio
10.6.5 Business performance
10.6.6 Key strategic moves and developments
10.7 Medtronic plc
10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Operating business segments
10.7.4 Product portfolio
10.7.5 Business performance
10.7.6 Key strategic moves and developments
10.8 Novo Nordisk A/S
10.8.1 Company overview
10.8.2 Company snapshot
10.8.3 Operating business segments
10.8.4 Product portfolio
10.8.5 Business performance
10.8.6 Key strategic moves and developments
10.9 Sanofi S.A.
10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Operating business segments
10.9.4 Product portfolio
10.9.5 Business performance
10.9.6 Key strategic moves and developments
10.10 Senseonics Holdings, Inc.
10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Operating business segments
10.10.4 Product portfolio
10.10.5 Business performance
10.10.6 Key strategic moves and developments
TABLE 1. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 2. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR INHALABLE INSULIN, BY REGION , 2020-2030,($MILLION)
TABLE 3. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET INHALABLE INSULIN BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ORAL INSULIN, BY REGION , 2020-2030,($MILLION)
TABLE 5. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ORAL INSULIN BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR INSULIN PATCHES, BY REGION , 2020-2030,($MILLION)
TABLE 7. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET INSULIN PATCHES BY COUNTRY, 2020-2030,($MILLION)
TABLE 8. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR CGM SYSTEMS, BY REGION , 2020-2030,($MILLION)
TABLE 9. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET CGM SYSTEMS BY COUNTRY, 2020-2030,($MILLION)
TABLE 10. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ARTIFICIAL PANCREAS, BY REGION , 2020-2030,($MILLION)
TABLE 11. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ARTIFICIAL PANCREAS BY COUNTRY, 2020-2030,($MILLION)
TABLE 12. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
TABLE 13. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ADULT POPULATION (>14YEARS), BY REGION , 2020-2030,($MILLION)
TABLE 14. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ADULT POPULATION (>14YEARS) BY COUNTRY, 2020-2030,($MILLION)
TABLE 15. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR CHILD POPULATION (14YEARS), BY REGION , 2020-2030,($MILLION)
TABLE 16. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET CHILD POPULATION (14YEARS) BY COUNTRY, 2020-2030,($MILLION)
TABLE 17. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 18. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR TYPE 1 DIABETES, BY REGION , 2020-2030,($MILLION)
TABLE 19. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET TYPE 1 DIABETES BY COUNTRY, 2020-2030,($MILLION)
TABLE 20. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR TYPE 2 DIABETES, BY REGION , 2020-2030,($MILLION)
TABLE 21. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET TYPE 2 DIABETES BY COUNTRY, 2020-2030,($MILLION)
TABLE 22. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 23. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR DIAGNOSTIC/CLINICS, BY REGION , 2020-2030,($MILLION)
TABLE 24. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET DIAGNOSTIC/CLINICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 25. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ICUS, BY REGION , 2020-2030,($MILLION)
TABLE 26. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ICUS BY COUNTRY, 2020-2030,($MILLION)
TABLE 27. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR HOME HEALTHCARE, BY REGION , 2020-2030,($MILLION)
TABLE 28. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET HOME HEALTHCARE BY COUNTRY, 2020-2030,($MILLION)
TABLE 29. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 30. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 31. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
TABLE 32. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 33. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 34. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 35. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 36. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 37. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 38. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 39. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 40. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 41. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 42. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 43. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 44. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 45. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 46. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 47. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 48. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
TABLE 49. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 50. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 51. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 52. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 53. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 54. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 55. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 56. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 57. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 58. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 59. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 60. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 61. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 62. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 63. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 64. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 65. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 66. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 67. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 68. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 69. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 70. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 71. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 72. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 73. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 74. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 75. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 76. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 77. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
TABLE 78. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 79. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 80. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 81. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 82. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 83. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 84. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 85. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 86. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 87. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 88. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 89. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 90. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 91. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 92. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 93. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 94. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 95. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 96. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 97. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 98. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 99. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 100. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 101. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 102. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 103. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 104. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 105. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 106. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
TABLE 107. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 108. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 109. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 110. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 111. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 112. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 113. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 114. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 115. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 116. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 117. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 118. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 119. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 120. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 121. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 122. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 123. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 124. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 125. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 126.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 127.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 128.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 129.ABBOTT LABORATORIES: NET SALES,
TABLE 130.ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 131.DEXCOM, INC: COMPANY SNAPSHOT
TABLE 132.DEXCOM, INC: OPERATING SEGMENTS
TABLE 133.DEXCOM, INC: PRODUCT PORTFOLIO
TABLE 134.DEXCOM, INC: NET SALES,
TABLE 135.DEXCOM, INC: KEY STRATERGIES
TABLE 136.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 137.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 138.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 139.ELI LILLY AND COMPANY: NET SALES,
TABLE 140.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 141.GLYSENS INCORPORATED: COMPANY SNAPSHOT
TABLE 142.GLYSENS INCORPORATED: OPERATING SEGMENTS
TABLE 143.GLYSENS INCORPORATED: PRODUCT PORTFOLIO
TABLE 144.GLYSENS INCORPORATED: NET SALES,
TABLE 145.GLYSENS INCORPORATED: KEY STRATERGIES
TABLE 146.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 147.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 148.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 149.JOHNSON & JOHNSON: NET SALES,
TABLE 150.JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 151.MANNKIND CORPORATION: COMPANY SNAPSHOT
TABLE 152.MANNKIND CORPORATION: OPERATING SEGMENTS
TABLE 153.MANNKIND CORPORATION: PRODUCT PORTFOLIO
TABLE 154.MANNKIND CORPORATION: NET SALES,
TABLE 155.MANNKIND CORPORATION: KEY STRATERGIES
TABLE 156.MEDTRONIC PLC: COMPANY SNAPSHOT
TABLE 157.MEDTRONIC PLC: OPERATING SEGMENTS
TABLE 158.MEDTRONIC PLC: PRODUCT PORTFOLIO
TABLE 159.MEDTRONIC PLC: NET SALES,
TABLE 160.MEDTRONIC PLC: KEY STRATERGIES
TABLE 161.NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 162.NOVO NORDISK A/S: OPERATING SEGMENTS
TABLE 163.NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 164.NOVO NORDISK A/S: NET SALES,
TABLE 165.NOVO NORDISK A/S: KEY STRATERGIES
TABLE 166.SANOFI S.A.: COMPANY SNAPSHOT
TABLE 167.SANOFI S.A.: OPERATING SEGMENTS
TABLE 168.SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 169.SANOFI S.A.: NET SALES,
TABLE 170.SANOFI S.A.: KEY STRATERGIES
TABLE 171.SENSEONICS HOLDINGS, INC.: COMPANY SNAPSHOT
TABLE 172.SENSEONICS HOLDINGS, INC.: OPERATING SEGMENTS
TABLE 173.SENSEONICS HOLDINGS, INC.: PRODUCT PORTFOLIO
TABLE 174.SENSEONICS HOLDINGS, INC.: NET SALES,
TABLE 175.SENSEONICS HOLDINGS, INC.: KEY STRATERGIES
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer